Invicta Diagnostic Ltd
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions [1]
- Market Cap ₹ 83.6 Cr.
- Current Price ₹ 66.5
- High / Low ₹ 105 / 58.1
- Stock P/E 18.8
- Book Value ₹ 39.7
- Dividend Yield 0.00 %
- ROCE 19.4 %
- ROE 14.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 7.46 | 7.99 | 30.10 | 32.35 | |
| 4.22 | 4.59 | 20.91 | 22.58 | |
| Operating Profit | 3.24 | 3.40 | 9.19 | 9.77 |
| OPM % | 43.43% | 42.55% | 30.53% | 30.20% |
| 0.00 | 0.35 | 0.09 | 0.69 | |
| Interest | 0.02 | 0.08 | 0.23 | 0.20 |
| Depreciation | 0.95 | 0.98 | 2.49 | 3.25 |
| Profit before tax | 2.27 | 2.69 | 6.56 | 7.01 |
| Tax % | 22.91% | 0.00% | 25.00% | 30.39% |
| 1.76 | 2.69 | 4.93 | 4.88 | |
| EPS in Rs | 204.56 | 5.81 | 3.91 | |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 37% |
| TTM: | -9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 21% |
| Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.13 | 8.42 | 12.57 | |
| Reserves | 12.05 | 5.18 | 37.35 | |
| 1.87 | 3.53 | 3.67 | ||
| 1.79 | 4.09 | 6.65 | ||
| Total Liabilities | 15.84 | 21.22 | 60.24 | |
| 11.78 | 9.58 | 19.20 | ||
| CWIP | 0.00 | 0.00 | 0.00 | |
| Investments | 0.00 | 4.33 | 6.20 | |
| 4.06 | 7.31 | 34.84 | ||
| Total Assets | 15.84 | 21.22 | 60.24 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 4.21 | 6.56 | 2.93 | ||
| -10.01 | -5.23 | -13.67 | ||
| 7.14 | -0.50 | 30.79 | ||
| Net Cash Flow | 1.34 | 0.83 | 20.05 | |
| Free Cash Flow | -8.56 | 6.23 | -9.93 | |
| CFO/OP | 124% | 71% | 40% |
Ratios
Consolidated / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 37.46 | 17.70 | 6.43 | |
| Inventory Days | 296.56 | 83.33 | 78.88 | |
| Days Payable | 1,102.60 | 70.00 | 254.03 | |
| Cash Conversion Cycle | -768.58 | 31.04 | -168.72 | |
| Working Capital Days | 5.94 | 18.55 | 55.74 | |
| ROCE % | 45.04% | 19.43% |
Insights
In beta| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Average revenue per test (ARPT) INR |
|
||
| Individual consumer business revenue share % |
|||
| Number of diagnostic centres centres |
|||
| Number of patients served patients |
|||
| Number of tests per patient visit tests per patient |
|||
| Number of tests performed tests |
|||
| Radiology revenue share % |
|||
Extracted by Screener AI
Documents
Announcements
-
Trading Window
- Trading window closes from 1 Oct 2026 until 48 hours after half-year results for 30 Sep 2026.
-
Shareholders meeting
- Invicta Diagnostic’s 3rd AGM on 19 Sep 2026 passed 4 resolutions, including MD appointment.
-
Shareholders meeting
- Invicta Diagnostic held its 3rd AGM on 19 Sept 2026, approved routine resolutions, and highlighted FY26 growth.
-
Outcome of Board Meeting
- Board approved AGM guidance; FY26 revenue ₹45-50 crore target, 11 centres, 2 labs, IPO ₹28.12 crore raised.
-
Commencement of commercial production/operations
- Shegaon CT and Pune pathology centres began commercial operations on 17 September 2026.
Concalls
-
May 2026Transcript PPT
Business Overview:[1]
IDL is a diagnostic services company operating across the MMR Region under the consumer brand P C Diagnostics, offering integrated radiology and pathology services with a focus on MRI, CT, and PET-CT. The company is supported by a structured hub-and-spoke network.